Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports

ABSTRACT The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.

Bibliographic Details

Main Authors:	Rocha-de-Lossada,Carlos, Linero,Carmen Alba, Ortega,Álvaro Santos, Calvo-de-Mora,Marina Rodríguez, Rachwani,Rahul, Borroni,Davide, Alba,Emilio, Orgaz,Manuel Benavides, Romano,Vito
Format:	Digital revista
Language:	English
Published:	Conselho Brasileiro de Oftalmologia 2022
Online Access:	http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492022000400411
Tags:	Add Tag No Tags, Be the first to tag this record!